Abivax S.A.

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: 61

Market Cap: $752.4M

Website

Introduction: Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Clinical Trials

Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients

Phase 2

Withdrawn

Conditions: Crohn Disease

Interventions: Drug: ABX464
Drug: Placebo

First Posted Date: 2019-04-05

Last Posted Date: 2024-07-31

Lead Sponsor: Abivax S.A.

Registration Number: NCT03905109

Locations: 🇧🇪
University Hospitals Leuven - campus Gasthuisberg, Leuven, Belgium

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: ABX196

First Posted Date: 2019-04-01

Last Posted Date: 2021-03-26

Lead Sponsor: Abivax S.A.

Target Recruit Count: 48

Registration Number: NCT03897543

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: ABX464 50mg
Drug: Matching Placebo
Drug: ABX464 100mg
Drug: Methotrexate

First Posted Date: 2019-01-23

Last Posted Date: 2023-02-15

Lead Sponsor: Abivax S.A.

Target Recruit Count: 60

Registration Number: NCT03813199

Locations: 🇧🇪
UZ Gent, Gent, Belgium
🇨🇿
Fakultni Tomayerova nemocnice, Praha, Czechia
🇨🇿
Revmatologicky ustav, Praha, Czechia

and more 21 locations

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: ABX464 25mg
Drug: ABX464 50mg
Drug: ABX464 100mg

First Posted Date: 2018-11-30

Last Posted Date: 2021-08-02

Lead Sponsor: Abivax S.A.

Target Recruit Count: 254

Registration Number: NCT03760003

Locations: 🇺🇸
Atlanta Center for Gastroenterology, P.C, Decatur, Georgia, United States
🇺🇸
UCSD Health System, San Diego, California, United States
🇺🇸
Central Texas Clinical Research, LLC, Austin, Texas, United States

and more 127 locations

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: ABX464

First Posted Date: 2017-12-11

Last Posted Date: 2025-03-05

Lead Sponsor: Abivax S.A.

Target Recruit Count: 22

Registration Number: NCT03368118

Locations: 🇧🇪
Department of Gastroenterology - University hospitals Leuven, Leuven, Belgium

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo oral capsule
Drug: ABX464

First Posted Date: 2017-03-28

Last Posted Date: 2024-06-03

Lead Sponsor: Abivax S.A.

Target Recruit Count: 32

Registration Number: NCT03093259

Locations: 🇦🇹
Univ.-Klinik für Innere Medizin I, Innsbruck, Austria
🇨🇿
Klinické centrum ISCARE, Praha, Czechia
🇫🇷
CHU de Nantes, Nantes, France

and more 16 locations

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

Phase 1

Completed

Conditions: HIV Infections
Health Volunteers

Interventions: Drug: ABX464 50mg
Drug: ABX464 150mg

First Posted Date: 2016-12-13

Last Posted Date: 2023-03-31

Lead Sponsor: Abivax S.A.

Target Recruit Count: 36

Registration Number: NCT02990325

Locations: 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Catalogna, Spain

ABX464 First in Man Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ABX464

First Posted Date: 2016-06-07

Last Posted Date: 2024-05-17

Lead Sponsor: Abivax S.A.

Target Recruit Count: 24

Registration Number: NCT02792686

Locations: 🇫🇷
Centre Cap, Montpellier, France

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

Phase 2

Completed

Conditions: HIV Infection

Interventions: Drug: Placebo
Drug: ABX464

First Posted Date: 2016-04-13

Last Posted Date: 2017-06-20

Lead Sponsor: Abivax S.A.

Target Recruit Count: 30

Registration Number: NCT02735863

Locations: 🇧🇪
C.H.U. Saint-Pierre, Bruxelles, Belgium
🇧🇪
Ghent University Hospital, Ghent, Belgium
🇧🇪
CHU Sart Tilman, Liège, Belgium

and more 5 locations

Food Effect on Pharmacokinetic Parameters of ABX464

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ABX464 Single dose
Drug: ABX464 Repeated dose

First Posted Date: 2016-04-08

Last Posted Date: 2016-04-08

Lead Sponsor: Abivax S.A.

Target Recruit Count: 48

Registration Number: NCT02731885

Locations: 🇲🇺
CAP Research, Sayed Hossen road, Phoenix, Mauritius

Home Terms & Conditions Privacy Policy